{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Myeloid+Leukemia%2C+Adult&page=2",
    "query": {
      "condition": "Acute Myeloid Leukemia, Adult",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Myeloid+Leukemia%2C+Adult&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T07:11:05.232Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01787474",
      "title": "Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Adult Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Filgrastim-sndz",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2014-05-19",
      "completion_date": "2021-06-17",
      "has_results": false,
      "last_update_posted_date": "2021-06-21",
      "last_synced_at": "2026-06-11T07:11:05.232Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01787474"
    },
    {
      "nct_id": "NCT00534001",
      "title": "Bupropion in Helping Adults Stop Smoking",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Cervical Cancer",
        "Esophageal Cancer",
        "Gastric Cancer",
        "Head and Neck Cancer",
        "Kidney Cancer",
        "Leukemia",
        "Liver Cancer",
        "Lung Cancer",
        "Pancreatic Cancer",
        "Tobacco Use Disorder"
      ],
      "interventions": [
        {
          "name": "bupropion hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 95,
      "start_date": "2006-01",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-06-11T07:11:05.232Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00534001"
    },
    {
      "nct_id": "NCT01118013",
      "title": "Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "donor lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "reduced-intensity transplant conditioning procedure",
          "type": "OTHER"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "Up to 69 Years"
      },
      "enrollment_count": 6,
      "start_date": "2010-12",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2017-03-24",
      "last_synced_at": "2026-06-11T07:11:05.232Z",
      "location_count": 10,
      "location_summary": "Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more",
      "locations": [
        {
          "city": "Lewes",
          "state": "Delaware"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Elkton MD",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01118013"
    },
    {
      "nct_id": "NCT03009240",
      "title": "Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Therapy-Related Acute Myeloid Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pevonedistat",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2017-08-21",
      "completion_date": "2026-03-19",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-06-11T07:11:05.232Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03009240"
    },
    {
      "nct_id": "NCT00949052",
      "title": "Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "polymorphism analysis",
          "type": "GENETIC"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "medical chart review",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "assessment of therapy complications",
          "type": "PROCEDURE"
        },
        {
          "name": "evaluation of cancer risk factors",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2009-01",
      "completion_date": "2018-02",
      "has_results": false,
      "last_update_posted_date": "2018-08-16",
      "last_synced_at": "2026-06-11T07:11:05.232Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00949052"
    },
    {
      "nct_id": "NCT02115295",
      "title": "Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Biphenotypic Leukemia",
        "Acute Myeloid Leukemia",
        "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Blasts 10 Percent or More of Bone Marrow Nucleated Cells",
        "Blasts 10 Percent or More of Peripheral Blood White Cells",
        "de Novo Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome",
        "Previously Treated Myelodysplastic Syndrome",
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Refractory Acute Myeloid Leukemia",
        "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Secondary Acute Myeloid Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Gilteritinib",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Midostaurin",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 508,
      "start_date": "2014-05-19",
      "completion_date": "2030-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-06-11T07:11:05.232Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02115295"
    },
    {
      "nct_id": "NCT03862157",
      "title": "Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative",
        "Chronic Eosinophilic Leukemia, Not Otherwise Specified",
        "Chronic Myelomonocytic Leukemia",
        "Chronic Neutrophilic Leukemia",
        "Essential Thrombocythemia",
        "Myelodysplastic Syndrome",
        "Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis",
        "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable",
        "Myeloid Neoplasm",
        "Myeloproliferative Neoplasm",
        "Myeloproliferative Neoplasm, Unclassifiable",
        "Overt Primary Myelofibrosis",
        "Polycythemia Vera",
        "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
        "Prefibrotic/Early Primary Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Pevonedistat",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2019-02-27",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-06-11T07:11:05.232Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03862157"
    },
    {
      "nct_id": "NCT04375631",
      "title": "CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Acute Myeloid Leukemia",
        "Recurrent Chronic Myelomonocytic Leukemia",
        "Recurrent Myelodysplastic Syndrome",
        "Refractory Acute Myeloid Leukemia",
        "Refractory Chronic Myelomonocytic Leukemia",
        "Refractory Mixed Phenotype Acute Leukemia",
        "Refractory Myelodysplastic Syndrome",
        "Refractory Acute Leukemia of Ambiguous Lineage",
        "Refractory Acute Undifferentiated Leukemia"
      ],
      "interventions": [
        {
          "name": "Cladribine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hematopoietic Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Sodium",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2020-12-03",
      "completion_date": "2027-03-17",
      "has_results": false,
      "last_update_posted_date": "2026-03-05",
      "last_synced_at": "2026-06-11T07:11:05.232Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04375631"
    },
    {
      "nct_id": "NCT05909501",
      "title": "Assessment of Geriatric Evaluations Impact on New AML Guidance",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "AML, Adult"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2023-10-25",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-06-11T07:11:05.232Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05909501"
    },
    {
      "nct_id": "NCT04512105",
      "title": "Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Chronic Lymphocytic Leukemia",
        "AML, Adult",
        "CLL",
        "CLL, Relapsed",
        "CLL, Refractory"
      ],
      "interventions": [
        {
          "name": "Pitavastatin",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2020-12-02",
      "completion_date": "2025-02-05",
      "has_results": false,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-06-11T07:11:05.232Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04512105"
    }
  ]
}